Skip to main content
. 2023 Feb 16;12(2):687–700. doi: 10.1007/s40120-023-00448-x

Table 3.

Anti-RBD IgG titer by duration of treatment

r p value
Ocrelizumab duration vs. anti-RBD IgG titer 0.009 0.973
Natalizumab duration vs. anti-RBD IgG titer − 0.122 0.707
Fumarate duration vs. anti-RBD IgG titer − 0.278 0.408
Interferon beta duration vs. anti-RBD IgG titer 0.828 0.042

Geometric mean titer values were compared using one-way analysis of variance with Tukey’s correction for multiple comparisons

Anti-RBD IgG SARS-CoV-2 spike receptor binding domain